Blount Kenneth F, Zhao Fang, Hermann Thomas, Tor Yitzhak
Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, California 92093-0358, USA.
J Am Chem Soc. 2005 Jul 13;127(27):9818-29. doi: 10.1021/ja050918w.
The lack of high RNA target selectivity displayed by aminoglycoside antibiotics results from both their electrostatically driven binding mode and their conformational adaptability. The inherent flexibility around their glycosidic bonds allows them to easily assume a variety of conformations, permitting them to structurally adapt to diverse RNA targets. This structural promiscuity results in the formation of aminoglycoside complexes with diverse RNA targets in which the antibiotics assume distinct conformations. Such differences suggest that covalently linking individual rings in an aminoglycoside could reduce its available conformations, thereby altering target selectivity. To explore this possibility, conformationally constrained neomycin and paromomycin analogues designed to mimic the A-site bound aminoglycoside structure have been synthesized and their affinities to the TAR and A-site, two therapeutically relevant RNA targets, have been evaluated. As per design, this constraint has minimal deleterious effect on binding to the A-site. Surprisingly, however, preorganizing these neomycin-class antibiotics into a TAR-disfavored structure has no deleterious effect on binding to this HIV-1 RNA sequence. We rationalize these observations by suggesting that the A-site and HIV TAR possess inherently different selectivities toward aminoglycosides. The inherent plasticity of the TAR RNA, coupled to the remaining flexibility within the conformationally constrained analogues, makes this RNA site an accommodating target for such polycationic ligands. In contrast, the deeply encapsulating A-site is a more discriminating RNA target. These observations suggest that future design of novel target selective RNA-based therapeutics will have to consider the inherent "structural" selectivity of the RNA target and not only the selectivity patterns displayed by the low molecular weight ligands.
氨基糖苷类抗生素缺乏高RNA靶点选择性,这是由其静电驱动的结合模式及其构象适应性共同导致的。其糖苷键周围固有的灵活性使它们能够轻松呈现多种构象,从而在结构上适应不同的RNA靶点。这种结构上的混杂性导致氨基糖苷类与多种RNA靶点形成复合物,其中抗生素呈现出不同的构象。这些差异表明,将氨基糖苷类中的各个环共价连接起来可以减少其可用构象,从而改变靶点选择性。为了探索这种可能性,已经合成了旨在模拟A位点结合的氨基糖苷类结构的构象受限新霉素和巴龙霉素类似物,并评估了它们对TAR和A位点这两个与治疗相关的RNA靶点的亲和力。按照设计,这种限制对与A位点的结合产生的有害影响最小。然而,令人惊讶的是,将这些新霉素类抗生素预组织成不利于TAR的结构对与这种HIV-1 RNA序列的结合没有有害影响。我们通过提出A位点和HIV TAR对氨基糖苷类具有本质上不同的选择性来解释这些观察结果。TAR RNA固有的可塑性,再加上构象受限类似物中剩余的灵活性,使得这个RNA位点成为此类聚阳离子配体的一个适应性靶点。相比之下,深度包封的A位点是一个更具选择性的RNA靶点。这些观察结果表明,未来基于RNA的新型靶点选择性疗法的设计将不得不考虑RNA靶点固有的“结构”选择性,而不仅仅是低分子量配体所显示的选择性模式。